The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.

Avid Bioservices Chief Executive Nick Green said the company’s board considered several options before determining to move ...

Avid Bioservices (CDMO) has agreed to be acquired by GHO Capital Partners and Ampersand Capital Partners through a cash deal that values the company at $1.1B. Read more here.

Avid Bioservices ( (CDMO) ) just unveiled an announcement. Avid Bioservices, a biologics contract development and manufacturing organization, ...

The $12.50-per-share takeover has been approved by Avid's board and is scheduled to close in the first quarter of 2025, ...

RBC Capital downgraded Avid Bioservices (CDMO) to Sector Perform from Outperform with a price target of $12.50, up from $12, after the company ...

Ademi LLP is investigating Avid (NASDAQ: CDMO) for possible breaches of fiduciary duty and other violations of law in its transaction with GHO and Ampersand. Click here to learn how to join our ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to ...

This week, biologics CDMO Avid Bioservices revealed that it’s agreed to be acquired by funds managed by Ampersand and British ...

Avid Bioservices shares were up 12% at $12.25 after getting a buyout offer from GHO Capital Partners and Ampersand Capital Partners. Under the terms of the buyout, Avid will be acquired by funds ...

Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high ...

The merger agreement is valued at approximately $1.1 billion. Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), announced on Nov. 6, 2024 that it has entered ...